Start date: 05 August 2022
End date: 04 August 2026
The aims of the MPX-RESPONSE project were to enhance understanding of mpox (Monkeypox), evaluate potential treatments, and bolster Europe's preparedness for emerging infectious disease outbreaks.
The expected outputs includes:
• Better clinical management of patients with mpox disease.
• Help advance our understanding of patients with mpox.
• Evaluate the safety and efficacy of tecovirimat, (or other antiviral drugs) for the treatment of mpox infection.
• Set-up innovative clinical trial designs for better preparedness against future outbreaks.
• Generate recommendations for future policy-making regarding pandemic preparedness.
Scientific coordinator of the project: Yazdan Yazdanpanah